Core Viewpoint - The strategic collaboration among Maiwei Biotech, Yingshi Intelligent, and Haoyuan Pharmaceutical aims to develop a novel ADC compound library targeting hundreds of sites, accelerating the industrialization of innovative ADC drugs [1] Group 1: Company Collaboration - Maiwei Biotech, Yingshi Intelligent, and Haoyuan Pharmaceutical have officially announced a strategic cooperation agreement [1] - The partnership focuses on screening and advancing next-generation ADC candidate molecules [1] - The collaboration is expected to enhance the innovation and commercialization of ADC drugs [1]